Trial Profile
A Phase 1b, Exploratory, Randomized, Partially Single Blinded, Placebo and Open Label Controlled, Parallel Group Study to Assess the Effects of HM11260C and an Active Comparator on Gastric Emptying and Beta-Cell Response in Subjects With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Efpeglenatide (Primary) ; Liraglutide
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Hanmi Pharmaceutical
- 03 Jun 2015 Data from this trial will be presented at the American Diabetes Association's 75th Scientific Sessions, according to a Hanmi Pharmaceuticals media release.
- 23 Feb 2014 New trial record